Additionally, HDAC6-regulated acetylation sites have been described as disease-specific markers for 3R/4R tauopathies and 3R tauopathies (126), which may indicate some differences in PTMs and even aggregation propensity of tau among different tauopathies. Here, HDAC6 is linked to tauopathy.